Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,349 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

Digital Behavioral Interventions in Inflammatory Bowel Disease

NCT04861597
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases, Stress, Psychological, Depression, Anxiety
Interventions
Internet based cognitive behavioral therapy, Digital mood tracking
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Completed Phase 1Phase 2 Interventional Results available

Intradiscal rhGDF-5 Phase I/II Clinical Trial

NCT00813813
Conditions
Degenerative Disc Disease
Interventions
Intradiscal rhGDF-5
Drug
Lead sponsor
DePuy Spine
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Durango, Colorado • Marietta, Georgia + 5 more
Conditions
Lung Cancer
Interventions
gene expression analysis, polymorphism analysis, protein expression analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Kidney Cancer
Interventions
Writing, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone, protein expression analysis, laboratory biomarker analysis
Dietary Supplement · Drug · Genetic + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Conditions
Anxiety Disorders
Interventions
Project EMPOWER, Being Brave Parent Education, Sharing Feelings
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Minneapolis, Minnesota • Rochester, Minnesota
Completed No phase listed Observational

CTC Immune Checkpoint

NCT02456571
Conditions
Prostate Cancer
Interventions
CTC biomarker expression prevalence
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Sodium Channel Expression in Human Teeth

NCT00575263
Conditions
Dental Pulp Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
16 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Fibromyalgia
Interventions
Affective Self-Awareness workshop
Behavioral
Lead sponsor
Mike Hsu
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Southfield, Michigan
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms

NCT00160472
Conditions
Ovarian Neoplasms
Interventions
removal of ovarian vessels
Procedure
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Pancreatic Cancer
Interventions
protein expression analysis, western blotting, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

Exploratory Study Of The ERCC-1 Gene

NCT00846482
Conditions
Colon Cancer, Rectal Cancer
Interventions
Oxaliplatin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
The Bronx, New York
Conditions
Sepsis, Non-Infectious Systemic Inflammatory Response Syndrome
Interventions
SeptiCyte (various)
Diagnostic Test
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Stroke, Cancer
Interventions
Blood tests, Transcranial Doppler Microemboli Detection Study
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of IFN-γ on Innate Immune Cells

NCT02609932
Conditions
Chronic Granulomatous Disease
Interventions
Administration of drug (Interferon-gamma 1-b) subcutaneously
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

Ethical, Legal, and Social Issues Substudy in Relation to the GTEx Project

NCT02887339
Conditions
Standard Training, Online Training
Interventions
Training Website, Control
Other
Lead sponsor
Temple University
Other
Eligibility
Not listed
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, mitoxantrone hydrochloride, pentostatin, fluorescence in situ hybridization, gene rearrangement analysis, polymerase chain reaction, protein expression analysis, flow cytometry, biopsy
Biological · Drug · Genetic + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Leber Congenital Amaurosis
Interventions
voretigene neparvovec-rzyl
Biological
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Knee Osteoarthritis
Interventions
Neuromuscular electrical stimulation (NMES), Standard Rehabilitation Protocol
Procedure · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Aurora, Colorado
Conditions
Leukemia
Interventions
microarray analysis, molecular genetic technique, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years to 59 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Columbus, Ohio
Completed No phase listed Observational

Identifying PARDS Endotypes

NCT03539783
Conditions
Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult
Interventions
Respiratory epithelial cell brushing
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 18 Years
Enrollment
76 participants
Timeline
2018 – 2022
U.S. locations
2
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

NCT06967181
Conditions
Mumps
Interventions
CVM150, CVM26, Placebo
Biological · Other
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 29 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • North Charleston, South Carolina